Famous biopharmaceutical thought chief provides tutorial, analysis and business experience
MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Firm”), an business chief in using beginning tissue as a platform for regenerative drugs, at the moment introduced the appointment of Phyllis Gardner, M.D. to its Board of Administrators. Regarded for her contributions and accomplishments throughout academia, biotechnology, and the healthcare business, Dr. Gardner, a professor of drugs on the Stanford College Faculty of Medication and distinguished enterprise chief, brings to MiMedx greater than 35 years of expertise, marked by quite a few nationwide awards and honors. She has performed in depth analysis in cell biology and gene remedy, and is broadly printed within the fields of cell biology and pharmacology.
Timothy R. Wright, MiMedx Chief Govt Officer, commented, “Dr. Gardner is a acknowledged knowledgeable in her fields, with excellent medical analysis expertise and coaching. Her perception, perspective and strategic experience shall be invaluable as we propel our late-stage pipeline towards biologic registration, and information MiMedx into the way forward for regenerative therapeutics.”
M. Kathleen Behrens, Ph.D., Chair of the MiMedx Board of Administrators, added, “We’re lucky to welcome Dr. Gardner to the MiMedx Board as a doctor, voice for science, and enterprise chief with company-building expertise and orientation towards medical innovation. Her probing mind and powerful moral compass distinguish her within the discipline of life sciences and her appointment displays our dedication to making sure we have now a various mixture of viewpoints and experience guiding the Firm’s future and course.”
“It’s with nice pleasure that I be part of an organization with such scientific potential to handle unmet medical wants, complemented by a uniquely completed Board of Administrators and Chief Govt Officer,” said Phyllis Gardner, M.D. “The sector of regenerative drugs and tissue expertise holds super promise, and I look ahead to aiding the Firm in attaining its aim of advancing the scientific rigor of the class in a means that makes a distinction for sufferers.”
About Phyllis Gardner, M.D.
Dr. Gardner has spent greater than 35 years in academia, drugs and business. She has served on the board of administrators of a number of private and non-private firms, together with Revance Therapeutics, Inc. since 2006, Corium Worldwide, Inc. from November 2007 to December 2018, and CohBar, Inc. from February 2019 to current. Dr. Gardner has additionally served as an advisor to Change Well being Care, Inc. from April 2019 to current. From June 1999 to July 2014, she served in varied capacities together with as an Adjunct Associate at Essex Woodlands Well being Ventures, a progress fairness agency that focuses on the healthcare business (and a predecessor agency to EW Healthcare Companions, a holder of MiMedx Sequence B Most popular Inventory). Moreover, Dr. Gardner has been a member of the Harvard Medical Faculty Board of Fellows since April 2013 and is a scientific reviewer for the Most cancers Prevention and Analysis Institute of Texas.
She started her tutorial medical profession at Stanford College, the place she has held a number of positions together with Senior Affiliate Dean for Schooling and Pupil Affairs and stays at the moment as Professor of Medication. From 1994 to 1998, she took a depart of absence from Stanford College to function Principal Scientist, Vice President of Analysis and Head of ALZA Know-how Institute, a significant drug supply firm.
Dr. Gardner earned a Bachelor of Science diploma in Biology from the College of Illinois and a Physician of Medication diploma from Harvard Medical Faculty. She educated in Inner Medication at Massachusetts Common Hospital, adopted by Chief Residency at Stanford College Hospital and post-doctoral fellowships at Columbia College and College School London.
MiMedx is an business chief in using beginning tissue as a platform for regenerative drugs, creating and distributing placental tissue allografts with patent-protected, proprietary processes for a number of sectors of healthcare. As a pioneer in placental biologics, we have now each a core enterprise, targeted on addressing the wants of sufferers with acute and power non-healing wounds, and a promising late-stage pipeline focused at lowering ache and bettering operate for sufferers with degenerative musculoskeletal circumstances. We derive our merchandise from human placental tissues and course of these tissues utilizing our proprietary processing strategies, together with the PURION® course of. We make use of Present Good Tissue Practices, Present Good Manufacturing Practices, and terminal sterilization to provide our allografts. MiMedx has provided over two million allografts, by each direct and consignment shipments. For extra data, please go to www.mimedx.com.